This case originated from allegations made by Ronald Streck, a lawyer and pharmacist, who accused Eli Lilly of violating the federal False Claims Act. The crux of Streck's argument revolved around Eli Lilly's practice of retroactively raising drug prices on products sold to wholesalers but not yet resold to pharmacies between 2005 and 2017.